Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Youths - Birth - 17
  • Idaho


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com

Aberdeen

Boise

Nampa

Pocatello

Idaho Falls

Meridian

Coeur D Alene

Twin Falls

Caldwell

Moscow

Rexburg


Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • Teen Success Project
    NCT03015805
    Condition:   Substance Abuse
    Interventions:   Behavioral: Contingency Management;   Behavioral: Probation as Usual
    Sponsors:   Oregon Social Learning Center;   George Mason University
    Recruiting
  • Scaling up Schoolwide Positive Behavioral Interventions and Supports (SWPBIS) in Rural Idaho Schools
    NCT03736395
    Condition:   Problem Behavior
    Interventions:   Behavioral: Idaho Rural Implementation Model;   Behavioral: Control
    Sponsors:   Boise State University;   U.S. Department of Justice
    Recruiting
  • A Post-Market Retrospective Study on Revision Total Knee Arthroplasty Using Medacta GMK® Revision Prosthesis
    NCT02912351
    Condition:   Osteoarthritis
    Intervention:   Other: Patient record review, Radiographs, and questionaires.
    Sponsor:   Medacta USA
    Recruiting
  • FreeStyle LIbre Flash Glucose Monitoring System Pediatric Accuracy Study
    NCT03820050
    Condition:   Diabetes Mellitus
    Intervention:   Device: Freestyle LIbre Flash Glucose Monitoring System
    Sponsor:   Abbott Diabetes Care
    Completed
  • FreeStyle Libre Flash Glucose Monitoring System Post Approval Study for Pediatric Patients
    NCT03448367
    Condition:   Diabetes Mellitus
    Intervention:   Device: FreeStyle Libre Flash Glucose Monitoring System
    Sponsor:   Abbott Diabetes Care
    Recruiting
  • Dextromethorphan Pediatric Acute Cough Study
    NCT02651116
    Condition:   Cough
    Interventions:   Drug: Dextromethorphan Hydrobromide;   Drug: Placebo;   Device: Cough recording device
    Sponsor:   Pfizer
    Recruiting
  • A Multi-centre, Prospective Surveillance to Assess Mid-term Performance of the Mpact Cup
    NCT02196818
    Conditions:   Osteoarthritis;   Arthritis;   Avascular Necrosis;   Fracture of the Femoral Neck or Head;   Congenital Hip Dysplasia
    Intervention:   Device: Mpact Acetabular Shell
    Sponsor:   Medacta International SA
    Recruiting
  • Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection
    NCT03656510
    Condition:   Respiratory Syncytial Virus Infections
    Interventions:   Drug: JNJ-53718678;   Drug: Placebo
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes
    NCT03740919
    Condition:   Type 1 Diabetes Mellitus
    Interventions:   Drug: LY900014;   Drug: Insulin Lispro
    Sponsor:   Eli Lilly and Company
    Recruiting
  • An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation
    NCT03120520
    Condition:   Chronic Idiopathic Constipation
    Interventions:   Drug: Plecanatide;   Drug: Matching placebo
    Sponsor:   Bausch Health Americas, Inc.
    Completed
  • Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler
    NCT02980133
    Condition:   Asthma
    Interventions:   Drug: Fp MDPI;   Drug: FS MDPI;   Drug: Placebo
    Sponsor:   Teva Branded Pharmaceutical Products, R&D Inc.
    Completed
  • Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia
    NCT03204916
    Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Other: Medical Chart Review;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
    NCT03067181
    Conditions:   Childhood Extracranial Germ Cell Tumor;   Extragonadal Embryonal Carcinoma;   Germ Cell Tumor;   Malignant Germ Cell Tumor;   Malignant Ovarian Teratoma;   Stage I Ovarian Choriocarcinoma;   Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage I Ovarian Teratoma AJCC v6 and v7;   Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage I Testicular Choriocarcinoma AJCC v6 and v7;   Stage I Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage I Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage II Ovarian Choriocarcinoma;   Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage II Testicular Choriocarcinoma AJCC v6 and v7;   Stage II Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage II Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage III Ovarian Choriocarcinoma;   Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage III Testicular Choriocarcinoma AJCC v6 and v7;   Stage III Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage III Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage IV Ovarian Choriocarcinoma;   Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7;   Testicular Mixed Choriocarcinoma and Embryonal Carcinoma;   Testicular Mixed Choriocarcinoma and Teratoma;   Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
    Interventions:   Other: Best Practice;   Drug: Bleomycin;   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
    NCT02567435
    Conditions:   Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma
    Interventions:   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate;   Drug: Vinorelbine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • SOFI: A Quality Improvement Project to Standardize Use of Intravenous Fluids in Hospitalized Pediatric Patients
    NCT03924674
    Conditions:   Intravenous Fluids;   Fluid and Electrolyte Imbalance;   ADH Inappropriate
    Intervention:   Other: Education, clinical decision support tools
    Sponsors:   Seattle Children's Hospital;   American Academy of Pediatrics
    Active, not recruiting
  • A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity
    NCT04102189
    Conditions:   Overweight;   Obesity
    Interventions:   Drug: Semaglutide;   Drug: Placebo
    Sponsor:   Novo Nordisk A/S
    Recruiting
  • Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity
    NCT02918279
    Conditions:   Metabolism and Nutrition Disorder;   Obesity
    Interventions:   Drug: Liraglutide;   Drug: Placebo
    Sponsor:   Novo Nordisk A/S
    Completed
  • Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV
    NCT03636906
    Condition:   Respiratory Syncytial Virus Infections
    Interventions:   Biological: Respiratory syncytial virus (RSV) vaccine GSK3389245A;   Biological: Bexsero;   Biological: Nimenrix;   Biological: Menveo;   Biological: Synflorix;   Drug: Placebo
    Sponsor:   GlaxoSmithKline
    Active, not recruiting
  • A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day
    NCT03878446
    Condition:   Short Stature Children Born Small for Gestational Age (SGA)
    Interventions:   Drug: somapacitan;   Drug: Norditropin®
    Sponsor:   Novo Nordisk A/S
    Recruiting
  • Low-Dose Atropine for Treatment of Myopia
    NCT03334253
    Condition:   Myopia
    Interventions:   Drug: Atropine;   Other: Placebo Eyedrops
    Sponsors:   Jaeb Center for Health Research;   Pediatric Eye Disease Investigator Group;   National Eye Institute (NEI)
    Recruiting
  • Growth and Tolerance of Infants Fed Milk-Based Infant Formula
    NCT03967132
    Condition:   Gastro-Intestinal Tolerance
    Interventions:   Other: Control Infant Formula;   Other: Experimental Infant Formula;   Other: Reference Group
    Sponsor:   Abbott Nutrition
    Recruiting
  • Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
    NCT02141074
    Conditions:   Congenital Bleeding Disorder;   Haemophilia B
    Intervention:   Drug: nonacog beta pegol
    Sponsor:   Novo Nordisk A/S
    Recruiting
  • Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
    NCT04074928
    Condition:   Influenza, Human
    Interventions:   Biological: QIVc;   Biological: Comparator QIV
    Sponsor:   Seqirus
    Recruiting
  • Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab
    NCT03875729
    Condition:   Type 1 Diabetes Mellitus
    Interventions:   Biological: teplizumab;   Biological: Placebo
    Sponsor:   Provention Bio, Inc.
    Recruiting
  • JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis
    NCT03796676
    Condition:   Atopic Dermatitis
    Interventions:   Drug: Placebo;   Drug: PF-04965842;   Drug: PF04965842
    Sponsor:   Pfizer
    Recruiting
  • A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)
    NCT03695237
    Condition:   Central Precocious Puberty (CPP)
    Intervention:   Drug: Leuprolide Acetate (LA)
    Sponsor:   AbbVie
    Recruiting
  • Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms
    NCT03653364
    Condition:   Influenza
    Intervention:   Drug: Baloxavir Marboxil
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric (7-17 Years) With Major Depressive Disorder
    NCT03569475
    Condition:   Major Depressive Disorder
    Interventions:   Drug: Levomilnacipran ER;   Drug: Fluoxetine;   Drug: Placebo
    Sponsor:   Allergan
    Recruiting
  • Assess the Mid-term Performance of the Mpact Cup in Subjects Requiring Total Hip Arthroplasty
    NCT03897595
    Condition:   Hip Osteoarthritis
    Intervention:   Device: Quadra®-H, Quadra®-C, AMIStem®-H or AMIStem®-C femoral stem and Mpact® Acetabular hip system with CoCr Femoral Head or Ceramic MectaCer BIOLOX® Femoral Head
    Sponsor:   Medacta USA
    Recruiting
  • Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US
    NCT03537508
    Condition:   Meningococcal Infections
    Interventions:   Biological: MenACYW conjugate vaccine;   Biological: MenACYW-135 conjugate vaccine;   Biological: DTaP-IPV//Hib vaccine;   Biological: Pneumococcal 13-valent conjugate vaccine;   Biological: Pentavalent rotavirus vaccine;   Biological: Hepatitis B vaccine;   Biological: Measles, mumps, rubella (MMR) vaccine;   Biological: Varicella vaccine;   Biological: Hepatitis A vaccine
    Sponsor:   Sanofi Pasteur, a Sanofi Company
    Recruiting
  • Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
    NCT03429543
    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: Linagliptin;   Drug: Empagliflozin;   Drug: Placebo
    Sponsor:   Boehringer Ingelheim
    Recruiting
  • Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
    NCT02968004
    Condition:   Pediatric Growth Hormone Deficiency
    Interventions:   Drug: MOD-4023;   Drug: Somatropin
    Sponsor:   OPKO Health, Inc.
    Active, not recruiting
  • Study to Assess the Safety and Efficacy of ONZETRA® Xsail® (Sumatriptan Nasal Powder) for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents
    NCT03338920
    Condition:   Acute Migraine With or Without Aura
    Interventions:   Drug: sumatriptan nasal powder;   Drug: Placebo
    Sponsor:   Currax Pharmaceuticals
    Active, not recruiting
  • Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years
    NCT03325881
    Condition:   Attention Deficit Hyperactivity Disorder (ADHD)
    Interventions:   Drug: SHP465;   Drug: Placebo
    Sponsor:   Shire
    Completed
  • Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
    NCT02914184
    Conditions:   Infections, Rotavirus;   Rotavirus Vaccines
    Interventions:   Biological: HRV PCV-free liquid vaccine;   Biological: Rotarix
    Sponsor:   GlaxoSmithKline
    Completed
  • A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis
    NCT03257644
    Condition:   Atopic Dermatitis
    Intervention:   Drug: Ruxolitinib phosphate cream
    Sponsor:   Incyte Corporation
    Recruiting
  • Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)
    NCT03239873
    Condition:   Varicella
    Interventions:   Biological: VARIVAX® PE34 Process;   Biological: VARIVAX® 2016 Commercial Process;   Biological: M-M-R II®
    Sponsor:   Merck Sharp & Dohme Corp.
    Completed
  • This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine
    NCT03207750
    Conditions:   Rotavirus Infection;   Rotavirus Vaccines
    Interventions:   Biological: Rotarix;   Biological: Pediarix;   Biological: Hiberix;   Biological: Prevenar 13
    Sponsor:   GlaxoSmithKline
    Completed
  • Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children
    NCT03126227
    Condition:   Peanut Allergy
    Interventions:   Biological: AR101;   Biological: Placebo
    Sponsor:   Aimmune Therapeutics, Inc.
    Completed
  • Binocular Dig Rush Game Treatment for Amblyopia
    NCT02983552
    Condition:   Amblyopia
    Interventions:   Other: iPad®;   Other: Spectacle correction
    Sponsors:   Jaeb Center for Health Research;   Pediatric Eye Disease Investigator Group;   National Eye Institute (NEI)
    Recruiting
  • A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes
    NCT02963766
    Condition:   Type 2 Diabetes
    Interventions:   Drug: Dulaglutide;   Drug: Placebo
    Sponsor:   Eli Lilly and Company
    Recruiting
  • A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)
    NCT02953314
    Condition:   Cystic Fibrosis
    Interventions:   Drug: TEZ;   Drug: TEZ/IVA;   Drug: IVA
    Sponsor:   Vertex Pharmaceuticals Incorporated
    Completed
  • Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures
    NCT02849626
    Condition:   Partial-Onset or Primary Generalized Tonic-Clonic Seizures
    Intervention:   Drug: Perampanel
    Sponsor:   Eisai Inc.
    Active, not recruiting
  • Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
    NCT02828358
    Conditions:   Acute Leukemia of Ambiguous Lineage;   B Acute Lymphoblastic Leukemia;   Mixed Phenotype Acute Leukemia
    Interventions:   Drug: Azacitidine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Prednisolone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Trial of Overminus Spectacle Therapy for Intermittent Exotropia
    NCT02807350
    Condition:   Intermittent Exotropia
    Interventions:   Device: Overminus treatment;   Device: Non-overminus treatment
    Sponsors:   Jaeb Center for Health Research;   Pediatric Eye Disease Investigator Group;   National Eye Institute (NEI)
    Active, not recruiting
  • Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
    NCT02618434
    Condition:   Attention Deficit Hyperactivity Disorder (ADHD)
    Interventions:   Drug: SPN-810;   Drug: Placebo
    Sponsor:   Supernus Pharmaceuticals, Inc.
    Completed
  • Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
    NCT02521493
    Conditions:   Acute Myeloid Leukemia;   Down Syndrome;   Myelodysplastic Syndrome;   Myeloid Leukemia Associated With Down Syndrome;   Myeloproliferative Neoplasm
    Interventions:   Drug: Asparaginase;   Drug: Asparaginase Erwinia chrysanthemi;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone;   Drug: Mitoxantrone Hydrochloride;   Drug: Thioguanine
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A
    NCT02137850
    Conditions:   Congenital Bleeding Disorder;   Haemophilia A
    Intervention:   Drug: turoctocog alfa pegol
    Sponsor:   Novo Nordisk A/S
    Enrolling by invitation
  • A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase
    NCT02369653
    Conditions:   Lymphoma;   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Apixaban;   Other: No systemic anticoagulant prophylaxis
    Sponsors:   Bristol-Myers Squibb;   Pfizer
    Recruiting
  • Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
    NCT02176967
    Conditions:   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Neuroblastoma
    Interventions:   Drug: Carboplatin;   Other: Clinical Observation;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants
    NCT02096263
    Conditions:   Poliomyelitis;   Diphtheria;   Haemophilus Influenzae Type b;   Tetanus;   Acellular Pertussis;   Hepatitis B
    Interventions:   Biological: Infanrix hexa;   Biological: Pediarix;   Biological: ActHIB;   Biological: Pentacel;   Biological: Engerix-B;   Biological: Infanrix;   Biological: Hiberix;   Biological: Prevnar13;   Biological: Rotarix
    Sponsor:   GlaxoSmithKline
    Completed
  • A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A
    NCT01731600
    Conditions:   Congenital Bleeding Disorder;   Haemophilia A
    Intervention:   Drug: turoctocog alfa pegol
    Sponsor:   Novo Nordisk A/S
    Completed
  • Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age
    NCT01702428
    Conditions:   Rubella;   Measles;   Mumps
    Interventions:   Biological: Priorix;   Biological: M-M-R II;   Biological: Varivax;   Biological: Havrix;   Biological: Prevnar 13
    Sponsor:   GlaxoSmithKline
    Completed
  • Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
    NCT01621802
    Condition:   Measles-Mumps-Rubella
    Interventions:   Biological: Priorix;   Biological: M-M-R II;   Biological: Kinrix;   Biological: ProQuad
    Sponsor:   GlaxoSmithKline
    Completed
  • Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
    NCT01460160
    Condition:   Leukemia, Pediatric
    Intervention:   Drug: Dasatinib
    Sponsors:   Bristol-Myers Squibb;   Children's Oncology Group;   EsPhALL
    Active, not recruiting
  • Study of Blood Samples From Newborns With Down Syndrome
    NCT00959283
    Condition:   Myeloid Proliferations Associated With Down Syndrome
    Interventions:   Other: Diagnostic Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease
    NCT00606346
    Conditions:   Crohn's Disease;   Ulcerative Colitis;   Indeterminate Colitis;   Inflammatory Bowel Diseases
    Interventions:   Biological: Anti TNF therapy including infliximab;   Drug: No Biologics
    Sponsor:   Janssen Biotech, Inc.
    Active, not recruiting
  • Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma
    NCT00499616
    Condition:   Neuroblastoma
    Interventions:   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: topotecan hydrochloride;   Drug: Isotretinoin;   Procedure: Surgery;   Drug: Filgrastim
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
    NCT00369317
    Conditions:   Childhood Acute Basophilic Leukemia;   Childhood Acute Eosinophilic Leukemia;   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myelomonocytic Leukemia (M4);   Childhood Myelodysplastic Syndromes;   de Novo Myelodysplastic Syndromes;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
    Interventions:   Drug: asparaginase;   Drug: daunorubicin hydrochloride;   Drug: cytarabine;   Drug: thioguanine;   Drug: etoposide;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Completed
  • Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
    NCT03907488
    Conditions:   Ann Arbor Stage III Hodgkin Lymphoma;   Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma;   Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma;   Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma;   Ann Arbor Stage IIIA Hodgkin Lymphoma;   Ann Arbor Stage IIIB Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma;   Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma;   Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma;   Ann Arbor Stage IVA Hodgkin Lymphoma;   Ann Arbor Stage IVB Hodgkin Lymphoma;   Classic Hodgkin Lymphoma;   Lymphocyte-Rich Classic Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Dacarbazine;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Biological: Filgrastim;   Biological: Nivolumab;   Biological: Pegfilgrastim;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Vinblastine;   Drug: Vinblastine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
    NCT03845296
    Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Loss of Heterozygosity;   Lung Non-Small Cell Squamous Carcinoma;   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Intervention:   Drug: Rucaparib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Evaluation of Mammographic Breast Density in Participants With Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502
    NCT03609021
    Conditions:   Breast Carcinoma;   Estrogen Receptor Negative;   Progesterone Receptor Negative
    Interventions:   Procedure: Screening Mammography;   Procedure: Biospecimen Collection
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
    NCT03377556
    Conditions:   ATM Gene Mutation;   ATR Gene Mutation;   BARD1 Gene Mutation;   BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   BRIP1 Gene Mutation;   CHEK1 Gene Mutation;   CHEK2 Gene Mutation;   FANCA Gene Mutation;   FANCC Gene Mutation;   FANCD2 Gene Mutation;   FANCF Gene Mutation;   FANCM Gene Mutation;   NBN Gene Mutation;   PALB2 Gene Mutation;   RAD51 Gene Mutation;   RAD51B Gene Mutation;   RAD54L Gene Mutation;   Recurrent Squamous Cell Lung Carcinoma;   RPA1 Gene Mutation;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Talazoparib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
    NCT03091660
    Conditions:   Stage 0 Bladder Urothelial Carcinoma;   Stage 0is Bladder Urothelial Carcinoma;   Stage I Bladder Urothelial Carcinoma
    Interventions:   Biological: BCG Solution;   Biological: BCG Tokyo-172 Strain Solution;   Biological: BCG Tokyo-172 Strain Vaccine;   Other: Laboratory Biomarker Analysis
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
    NCT02642042
    Conditions:   KRAS Gene Mutation;   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Non-Small Cell Cancer AJCC v7
    Interventions:   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis;   Drug: Trametinib
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
    NCT02180867
    Conditions:   Alveolar Soft Part Sarcoma;   Angiomatoid Fibrous Histiocytoma;   Atypical Fibroxanthoma;   Clear Cell Sarcoma of Soft Tissue;   Epithelioid Malignant Peripheral Nerve Sheath Tumor;   Epithelioid Sarcoma;   Extraskeletal Myxoid Chondrosarcoma;   Extraskeletal Osteosarcoma;   Fibrohistiocytic Neoplasm;   Fibrosarcoma;   Glomus Tumor of the Skin;   Inflammatory Myofibroblastic Tumor;   Intimal Sarcoma;   Leiomyosarcoma;   Liposarcoma;   Low Grade Fibromyxoid Sarcoma;   Low Grade Myofibroblastic Sarcoma;   Malignant Cutaneous Granular Cell Tumor;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Triton Tumor;   Mesenchymal Chondrosarcoma;   Myxofibrosarcoma;   Myxoid Chondrosarcoma;   Myxoinflammatory Fibroblastic Sarcoma;   Nerve Sheath Neoplasm;   PEComa;   Pericytic Neoplasm;   Plexiform Fibrohistiocytic Tumor;   Sclerosing Epithelioid Fibrosarcoma;   Stage IB Soft Tissue Sarcoma AJCC v7;   Stage IIB Soft Tissue Sarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Synovial Sarcoma;   Undifferentiated (Embryonal) Sarcoma;   Undifferentiated High Grade Pleomorphic Sarcoma of Bone
    Interventions:   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Ifosfamide;   Drug: Pazopanib;   Drug: Pazopanib Hydrochloride;   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery
    Sponsor:   National Cancer Institute (NCI)
    Completed
  • Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
    NCT01274338
    Conditions:   Melanoma of Unknown Primary;   Recurrent Melanoma;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7
    Interventions:   Biological: Ipilimumab;   Other: Quality-of-Life Assessment;   Biological: Recombinant Interferon Alfa-2b
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
    NCT00874211
    Conditions:   Breast Cancer;   Lung Cancer;   Metastatic Cancer;   Multiple Myeloma;   Plasma Cell Neoplasm;   Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
    Intervention:   Procedure: assessment of therapy complications
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Novartis
    Completed
  • Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
    NCT03605862
    Conditions:   Enterovirus;   Rhinovirus
    Interventions:   Drug: Nitazoxanide;   Drug: Placebo
    Sponsor:   Romark Laboratories L.C.
    Completed
  • Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
    NCT03422822
    Condition:   Dermatitis, Atopic
    Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting
  • CLUSTER Trial for Outbreak Detection and Response
    NCT04053075
    Condition:   Cluster Detection
    Interventions:   Other: Routine cluster detection;   Other: Enhanced cluster detection
    Sponsors:   Harvard Pilgrim Health Care;   Hospital Corporation of America (HCA) Healthcare;   Brigham and Women's Hospital;   University of California, Irvine;   Harvard School of Public Health;   Rush University;   Duke University;   University of Massachusetts, Amherst;   University of California, San Francisco;   Cook County Health & Hospitals System;   Centers for Disease Control and Prevention
    Recruiting
  • A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis
    NCT04040192
    Condition:   Atopic Dermatitis
    Interventions:   Drug: Crisaborole 2%;   Drug: Vehicle
    Sponsor:   Pfizer
    Recruiting
  • An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
    NCT03749447
    Conditions:   Chronic Kidney Diseases;   Alport Syndrome
    Intervention:   Drug: Bardoxolone methyl
    Sponsor:   Reata Pharmaceuticals, Inc.
    Recruiting
  • Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis
    NCT03575871
    Condition:   Dermatitis, Atopic
    Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
    Sponsor:   Pfizer
    Completed
  • A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications
    NCT03381196
    Condition:   Influenza A
    Interventions:   Drug: Pimodivir 600 mg;   Drug: Placebo;   Other: SOC Treatment
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma
    NCT03358147
    Condition:   Asthma
    Interventions:   Drug: GP MDI 28.8 μg;   Drug: GP MDI 14.4 μg;   Drug: GP MDI 7.2 μg;   Drug: Placebo MDI;   Drug: Spiriva Respimat 2.5 μg
    Sponsor:   Pearl Therapeutics, Inc.
    Completed
  • Mupirocin-Iodophor ICU Decolonization Swap Out Trial
    NCT03140423
    Condition:   Staphylococcus Aureus
    Interventions:   Drug: Arm 1. Routine Care (Mupirocin/CHG);   Drug: Arm 2. Iodophor/CHG Decolonization
    Sponsors:   Harvard Pilgrim Health Care;   Hospital Corporation of America;   University of California, Irvine;   University of Massachusetts, Amherst;   Rush University;   Centers for Disease Control and Prevention
    Active, not recruiting
  • Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy
    NCT04056299
    Condition:   Hen Egg Allergy
    Interventions:   Biological: AR201 Powder;   Biological: Placebo powder
    Sponsor:   Aimmune Therapeutics, Inc.
    Recruiting
  • Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households
    NCT03969212
    Condition:   Influenza
    Interventions:   Drug: Baloxavir Marboxil;   Drug: Placebo
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • A Study to Determine the Outcomes of Patients With Localized B Cell Lymphoblastic Lymphoma (B-LLy) When Treated With Standard Risk B-ALL Therapy
    NCT03914625
    Conditions:   B Acute Lymphoblastic Leukemia;   B Lymphoblastic Lymphoma;   Down Syndrome
    Interventions:   Drug: Asparaginase Erwinia chrysanthemi;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Mercaptopurine Oral Suspension;   Drug: Methotrexate;   Drug: Prednisolone;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
    NCT03698994
    Conditions:   Advanced Malignant Solid Neoplasm;   MAPK1 Gene Mutation;   Recurrent Ependymal Tumor;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Histiocytic and Dendritic Cell Neoplasm;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Ependymoma;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Histiocytic and Dendritic Cell Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Wilms Tumor
    Interventions:   Other: Pharmacokinetic Study;   Drug: Ulixertinib
    Sponsor:   National Cancer Institute (NCI)
    Suspended
  • Evaluation of Efficacy, Safety and Tolerability of VeraCept IUD
    NCT03633799
    Condition:   Women at Risk for Pregnancy
    Intervention:   Drug: VeraCept
    Sponsors:   Sebela Pharmaceuticals Inc.;   Synteract, Inc.
    Active, not recruiting
  • Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
    NCT03533582
    Conditions:   Childhood Hepatocellular Carcinoma;   Childhood Malignant Liver Neoplasm;   Hepatoblastoma;   Hepatocellular Malignant Neoplasm, Not Otherwise Specified;   SMARCB1 Gene Mutation
    Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Fluorouracil;   Drug: Gemcitabine;   Drug: Irinotecan;   Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Other: Patient Observation;   Drug: Sorafenib;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
    NCT03526250
    Conditions:   Advanced Malignant Solid Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Kidney Wilms Tumor;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Ependymoma;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Palbociclib;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • AR101 Real-World Open-Label Extension Study
    NCT03337542
    Condition:   Peanut Allergy
    Intervention:   Biological: AR101
    Sponsor:   Aimmune Therapeutics, Inc.
    Completed
  • Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)
    NCT03245840
    Condition:   Eosinophilic Esophagitis (EoE)
    Intervention:   Drug: Budesonide oral suspension
    Sponsor:   Shire
    Recruiting
  • Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
    NCT03233204
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Low Grade Glioma;   Malignant Glioma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Rhabdoid Tumor;   Wilms Tumor
    Intervention:   Drug: Olaparib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
    NCT03220035
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Ependymoma;   Ewing Sarcoma;   Hepatoblastoma;   Langerhans Cell Histiocytosis;   Malignant Germ Cell Tumor;   Malignant Glioma;   Osteosarcoma;   Peripheral Primitive Neuroectodermal Tumor;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Rhabdomyosarcoma;   Soft Tissue Sarcoma;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Vemurafenib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
    NCT03213704
    Conditions:   Advanced Malignant Solid Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Wilms Tumor
    Interventions:   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
    NCT03213691
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Selumetinib;   Drug: Selumetinib Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Suspended
  • PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
    NCT03213678
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Samotolisib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
    NCT03213665
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Hodgkin Lymphoma;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   EZH2 Gene Mutation;   Low Grade Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Hodgkin Lymphoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Hodgkin Lymphoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Soft Tissue Sarcoma;   Rhabdoid Tumor;   SMARCA4 Gene Inactivation;   SMARCB1 Gene Inactivation;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Tazemetostat
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
    NCT03213652
    Conditions:   Advanced Malignant Solid Neoplasm;   ALK Fusion Protein Expression;   ALK Gene Mutation;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   ROS1 Fusion Positive;   ROS1 Gene Mutation
    Interventions:   Drug: Ensartinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
    NCT03210714
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Low Grade Glioma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Wilms Tumor
    Interventions:   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus Aged 10 to Below 18 Years Old
    NCT03199053
    Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: Dapagliflozin;   Drug: Saxagliptin;   Drug: Placebo
    Sponsor:   AstraZeneca
    Recruiting
  • Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
    NCT03155620
    Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Histiocytic Sarcoma;   Juvenile Xanthogranuloma;   Langerhans Cell Histiocytosis;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
    Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Drug: Ensartinib;   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Procedure: Mutation Carrier Screening;   Drug: Olaparib;   Drug: Palbociclib;   Other: Pharmacological Study;   Drug: Samotolisib;   Drug: Selumetinib Sulfate;   Drug: Tazemetostat;   Drug: Ulixertinib;   Drug: Vemurafenib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
    NCT03007147
    Conditions:   B Acute Lymphoblastic Leukemia;   BCR-ABL1 Fusion Protein Expression;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Dexrazoxane Hydrochloride;   Drug: Doxorubicin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Pegaspargase;   Drug: Prednisolone;   Other: Questionnaire Administration;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University of Milano Bicocca
    Recruiting
  • PALISADE Follow-on Study (ARC004)
    NCT02993107
    Condition:   Peanut Allergy
    Intervention:   Biological: AR101
    Sponsor:   Aimmune Therapeutics, Inc.
    Completed
  • Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination
    NCT02986854
    Condition:   Infections, Meningococcal
    Intervention:   Biological: Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)
    Sponsor:   GlaxoSmithKline
    Completed
  • Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
    NCT02981628
    Conditions:   Recurrent B Acute Lymphoblastic Leukemia;   Recurrent B Lymphoblastic Lymphoma;   Refractory B Acute Lymphoblastic Leukemia;   Refractory B Lymphoblastic Lymphoma
    Interventions:   Biological: Inotuzumab Ozogamicin;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Suspended
  • Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
    NCT02883049
    Conditions:   B Acute Lymphoblastic Leukemia;   Central Nervous System Leukemia;   Ph-Like Acute Lymphoblastic Leukemia;   Testicular Leukemia
    Interventions:   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
    NCT02867592
    Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes
    NCT02846545
    Condition:   Diabetes Mellitus, Type 1
    Interventions:   Biological: Golimumab;   Biological: Placebo
    Sponsor:   Janssen Research & Development, LLC
    Active, not recruiting
  • Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
    NCT02724579
    Conditions:   CTNNB1 Gene Mutation;   Medulloblastoma;   Wnt Positive
    Interventions:   Drug: Cisplatin;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Drug: Lomustine;   Radiation: Radiation Therapy;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Neuroblastoma Maintenance Therapy Trial
    NCT02679144
    Condition:   Neuroblastoma
    Intervention:   Drug: Difluoromethylornithine (DFMO)
    Sponsors:   Giselle Sholler;   KC Pharma;   Beat NB Cancer Foundation
    Recruiting
  • Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)
    NCT02635776
    Condition:   Peanut Allergy
    Interventions:   Biological: AR101 powder provided in capsules & sachets;   Biological: Placebo powder provided in capsules & sachets
    Sponsor:   Aimmune Therapeutics, Inc.
    Completed
  • Study of Two Surgical Drilling Techniques to Treat Juvenile Osteochondritis Dissecans of the Knee
    NCT01754298
    Condition:   Juvenile Osteochondritis Dissecans
    Interventions:   Procedure: Retro-articular drilling;   Procedure: Trans-articular drilling
    Sponsors:   Boston Children’s Hospital;   Pediatric Orthopaedic Society of North America;   University of Pennsylvania;   Tennessee Orthopedic Alliance;   Children's Hospital Medical Center, Cincinnati;   Children's Hospital and Health System Foundation, Wisconsin;   Washington University School of Medicine;   The Hospital for Sick Children;   Children's Hospital of Philadelphia;   Kaiser Permanente;   Rady Children's Hospital, San Diego;   St. Luke's Children's Hospital;   Medical College of Wisconsin;   Connecticut Children's Medical Center;   Hospital for Special Surgery, New York
    Active, not recruiting
  • A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved
    NCT02605837
    Condition:   Eosinophilic Esophagitis (EoE)
    Interventions:   Drug: Oral Budesonide Suspension (OBS);   Drug: Placebo
    Sponsor:   Shire
    Completed
  • Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
    NCT02559778
    Condition:   Neuroblastoma
    Interventions:   Drug: Ceritinib;   Drug: dasatinib;   Drug: sorafenib;   Drug: vorinostat;   Drug: DFMO
    Sponsors:   Giselle Sholler;   Dell, Inc.;   Beat NB Cancer Foundation
    Recruiting
  • Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
    NCT02484443
    Conditions:   Metastatic Malignant Neoplasm in the Lung;   Metastatic Osteosarcoma;   Recurrent Osteosarcoma
    Interventions:   Biological: Dinutuximab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Biological: Sargramostim
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
    NCT02470091
    Conditions:   Metastatic Osteosarcoma;   Recurrent Osteosarcoma;   Refractory Osteosarcoma;   Stage IV Osteosarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7
    Interventions:   Biological: Denosumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
    NCT02452554
    Conditions:   Pleuropulmonary Blastoma;   Recurrent Malignant Peripheral Nerve Sheath Tumor;   Recurrent Neuroblastoma;   Recurrent Rhabdomyosarcoma;   Recurrent Synovial Sarcoma;   Wilms Tumor
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Lorvotuzumab Mertansine;   Other: Pharmacological Study
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
    NCT02339740
    Condition:   Acute Promyelocytic Leukemia With PML-RARA
    Interventions:   Drug: Arsenic Trioxide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Idarubicin;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Tretinoin
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
    NCT02306161
    Conditions:   Metastatic Ewing Sarcoma;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Bone Marrow;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone;   Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Biological: Ganitumab;   Drug: Ifosfamide;   Radiation: Stereotactic Radiosurgery;   Procedure: Therapeutic Surgical Procedure;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB or Stage IIIB-IVB Hodgkin Lymphoma
    NCT02166463
    Conditions:   Ann Arbor Stage IIB Hodgkin Lymphoma;   Ann Arbor Stage IIIB Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IVA Hodgkin Lymphoma;   Ann Arbor Stage IVB Hodgkin Lymphoma;   Childhood Hodgkin Lymphoma;   Classic Hodgkin Lymphoma
    Interventions:   Biological: Bleomycin Sulfate;   Drug: Brentuximab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
    NCT02112916
    Conditions:   Adult T Acute Lymphoblastic Leukemia;   Ann Arbor Stage II Adult Lymphoblastic Lymphoma;   Ann Arbor Stage II Childhood Lymphoblastic Lymphoma;   Ann Arbor Stage III Adult Lymphoblastic Lymphoma;   Ann Arbor Stage III Childhood Lymphoblastic Lymphoma;   Ann Arbor Stage IV Adult Lymphoblastic Lymphoma;   Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma;   Childhood T Acute Lymphoblastic Leukemia
    Interventions:   Drug: Bortezomib;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Drug: Ifosfamide;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
    NCT02101853
    Condition:   B Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Asparaginase;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Mitoxantrone Hydrochloride;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
    NCT02054156
    Condition:   Cystic Fibrosis
    Interventions:   Drug: azithromycin;   Drug: placebo;   Drug: Tobramycin solution for inhalation
    Sponsors:   Bonnie Ramsey;   National Heart, Lung, and Blood Institute (NHLBI)
    Completed
  • Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
    NCT01979536
    Conditions:   Anaplastic Large Cell Lymphoma, ALK-Positive;   Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma;   Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma;   Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma;   CD30-Positive Neoplastic Cells Present
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ifosfamide;   Drug: Methotrexate
    Sponsor:   National Cancer Institute (NCI)
    Suspended
  • Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas
    NCT01793233
    Conditions:   Anaplastic Large Cell Lymphoma;   Burkitt Lymphoma;   Diffuse Large B-Cell Lymphoma;   Hodgkin Lymphoma;   Lymphoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma
    NCT01780662
    Conditions:   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Hodgkin Lymphoma;   Refractory Childhood Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Drug: Gemcitabine Hydrochloride
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
    NCT01602666
    Conditions:   Central Nervous System Nongerminomatous Germ Cell Tumor;   Childhood Central Nervous System Germinoma
    Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Radiation: Intensity-Modulated Radiation Therapy
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
    NCT01553149
    Conditions:   Neurofibromatosis Type 1;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Visual Pathway Glioma
    Interventions:   Drug: Lenalidomide;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
    NCT01371981
    Conditions:   Acute Myeloid Leukemia;   Leukemia Cutis;   Myeloid Neoplasm;   Myeloid Sarcoma;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Myeloid Neoplasm
    Interventions:   Drug: Asparaginase;   Drug: Bortezomib;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Sorafenib Tosylate
    Sponsor:   National Cancer Institute (NCI)
    Completed
  • Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
    NCT01307579
    Conditions:   Acute Myeloid Leukemia;   Adult Acute Monoblastic Leukemia;   Adult Acute Monocytic Leukemia;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With Maturation;   Adult Acute Myeloid Leukemia With Minimal Differentiation;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A;   Adult Acute Myeloid Leukemia Without Maturation;   Adult Acute Myelomonocytic Leukemia;   Alkylating Agent-Related Acute Myeloid Leukemia;   Childhood Acute Monoblastic Leukemia;   Childhood Acute Monocytic Leukemia;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Acute Myeloid Leukemia With Maturation;   Childhood Acute Myeloid Leukemia With Minimal Differentiation;   Childhood Acute Myeloid Leukemia Without Maturation;   Childhood Acute Myelomonocytic Leukemia;   Fungal Infection;   Myeloid Neoplasm;   Neutropenia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Myeloid Neoplasm
    Interventions:   Drug: Caspofungin Acetate;   Drug: Fluconazole;   Other: Laboratory Biomarker Analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
    NCT01231906
    Conditions:   Non-Metastatic Extraskeletal Ewing Sarcoma;   Peripheral Primitive Neuroectodermal Tumor of Bone;   Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Topotecan Hydrochloride;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
    NCT00137969
    Condition:   Lupus Erythematosus, Systemic
    Interventions:   Drug: Rituximab;   Drug: Placebo;   Drug: Prednisone;   Drug: Acetaminophen;   Drug: Diphenhydramine
    Sponsor:   Genentech, Inc.
    Completed
  • Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
    NCT01217437
    Conditions:   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified
    Interventions:   Biological: Bevacizumab;   Drug: Irinotecan Hydrochloride;   Drug: Temozolomide
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
    NCT01190930
    Conditions:   Acute Lymphoblastic Leukemia;   Adult B Lymphoblastic Lymphoma;   Ann Arbor Stage I B Lymphoblastic Lymphoma;   Ann Arbor Stage II B Lymphoblastic Lymphoma;   Childhood B Acute Lymphoblastic Leukemia;   Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Childhood B Lymphoblastic Lymphoma;   Down Syndrome;   Hypodiploid B Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
    NCT01142427
    Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
    NCT01096368
    Conditions:   Cellular Ependymoma;   Childhood Anaplastic Ependymoma;   Childhood Infratentorial Ependymoma;   Childhood Supratentorial Ependymoma;   Clear Cell Ependymoma;   Ependymoma;   Papillary Ependymoma
    Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Carboplatin;   Drug: Cisplatin;   Other: Clinical Observation;   Drug: Cyclophosphamide;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Vincristine Sulfate Liposome
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
    NCT00980460
    Conditions:   PRETEXT Stage 1 Hepatoblastoma;   PRETEXT Stage 2 Hepatoblastoma;   PRETEXT Stage 3 Hepatoblastoma;   PRETEXT Stage 4 Hepatoblastoma
    Interventions:   Drug: Cisplatin;   Drug: Dexrazoxane;   Drug: Doxorubicin Hydrochloride;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Procedure: Liver Transplantation;   Drug: Temsirolimus;   Procedure: Therapeutic Conventional Surgery;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Active, not recruiting
  • Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
    NCT00945009
    Conditions:   Adult Kidney Wilms Tumor;   Beckwith-Wiedemann Syndrome;   Childhood Kidney Wilms Tumor;   Diffuse Hyperplastic Perilobar Nephroblastomatosis;   Hemihypertrophy;   Rhabdoid Tumor of the Kidney;   Stage I Kidney Wilms Tumor;   Stage II Kidney Wilms Tumor;   Stage III Kidney Wilms Tumor;   Stage IV Kidney Wilms Tumor;   Stage V Kidney Wilms Tumor
    Interventions:   Biological: Dactinomycin;   Drug: Doxorubicin Hydrochloride;   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
    NCT00919269
    Conditions:   Adult Rhabdomyosarcoma;   Childhood Desmoplastic Small Round Cell Tumor;   Chordoma;   Desmoid-Type Fibromatosis;   Metastatic Childhood Soft Tissue Sarcoma;   Non-Metastatic Childhood Soft Tissue Sarcoma;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Rhabdomyosarcoma;   Stage I Adult Soft Tissue Sarcoma AJCC v7;   Stage II Adult Soft Tissue Sarcoma AJCC v7;   Stage III Adult Soft Tissue Sarcoma AJCC v7;   Stage IV Adult Soft Tissue Sarcoma AJCC v7;   Untreated Childhood Rhabdomyosarcoma
    Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Collecting and Storing Biological Samples From Patients With Ewing Sarcoma
    NCT00899990
    Conditions:   Askin Tumor;   Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
    Intervention:   Other: Laboratory Biomarker Analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Study of Kidney Tumors in Younger Patients
    NCT00898365
    Conditions:   Adult Cystic Nephroma;   Anaplastic Kidney Wilms Tumor;   Angiolipoma;   Cellular Congenital Mesoblastic Nephroma;   Classic Congenital Mesoblastic Nephroma;   Clear Cell Sarcoma of the Kidney;   Congenital Mesoblastic Nephroma;   Cystic Partially Differentiated Kidney Nephroblastoma;   Diffuse Hyperplastic Perilobar Nephroblastomatosis;   Extrarenal Rhabdoid Tumor;   Kidney Medullary Carcinoma;   Kidney Neoplasm;   Kidney Oncocytoma;   Kidney Wilms Tumor;   Metanephric Adenofibroma;   Metanephric Adenoma;   Metanephric Stromal Tumor;   Metanephric Tumor;   Mixed Congenital Mesoblastic Nephroma;   Ossifying Renal Tumor of Infancy;   Papillary Renal Cell Carcinoma;   Renal Cell Carcinoma;   Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions;   Rhabdoid Tumor of the Kidney;   Wilms Tumor
    Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Suspended
  • Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
    NCT00897325
    Conditions:   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Non-Hodgkin Lymphoma
    Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
    NCT00408005
    Conditions:   T Acute Lymphoblastic Leukemia;   T Lymphoblastic Lymphoma
    Interventions:   Drug: Asparaginase;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Nelarabine;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Completed
  • Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
    NCT00392327
    Conditions:   Anaplastic Medulloblastoma;   Medulloblastoma
    Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
    NCT00379340
    Conditions:   Stage III Wilms Tumor With Loss of Heterozygosity (LOH) for 1p and 16q;   Stage IV Wilms Tumor
    Interventions:   Drug: doxorubicin hydrochloride;   Drug: liposomal vincristine sulfate;   Procedure: conventional surgery;   Radiation: 3-dimensional conformal radiation therapy;   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: etoposide
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Completed
  • Radiation Therapy in Treating Young Patients With Gliomas
    NCT00238264
    Conditions:   Brain Tumor;   Central Nervous System Tumor
    Intervention:   Radiation: radiation therapy
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Completed
  • Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors
    NCT00082745
    Condition:   Childhood Malignant Neoplasm
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Dexamethasone Compared With Prednisone During Induction Therapy and MTX With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
    NCT00075725
    Condition:   Leukemia
    Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Completed
  • Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
    NCT00075582
    Conditions:   Adult Rhabdomyosarcoma;   Embryonal Childhood Rhabdomyosarcoma;   Embryonal-botryoid Childhood Rhabdomyosarcoma;   Previously Untreated Childhood Rhabdomyosarcoma
    Interventions:   Procedure: conventional surgery;   Drug: dactinomycin;   Drug: cyclophosphamide;   Drug: vincristine sulfate;   Radiation: radiation therapy
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting
  • Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma
    NCT00027846
    Conditions:   Brain Tumor;   Central Nervous System Tumor
    Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: vincristine sulfate;   Radiation: radiation therapy;   Drug: Mesna;   Procedure: therapeutic conventional surgery
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Completed
  • Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma
    NCT00004228
    Condition:   Lymphoma
    Interventions:   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Completed
  • Safety and Tolerability Study of Diazepam Buccal Soluble Film (DBSF) in Subjects With Epilepsy
    NCT03428360
    Condition:   Epilepsy
    Intervention:   Drug: Diazepam Buccal Soluble Film 5, 7.5,10, 12.5, and 15 mg
    Sponsors:   Aquestive Therapeutics;   Inventiv Health;   Covance
    Recruiting
  • A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)
    NCT03460990
    Condition:   Cystic Fibrosis
    Interventions:   Drug: VX-659/TEZ/IVA;   Drug: TEZ/IVA;   Drug: IVA;   Drug: Placebo
    Sponsor:   Vertex Pharmaceuticals Incorporated
    Completed
  • Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis
    NCT03916081
    Condition:   Atopic Dermatitis
    Interventions:   Drug: ARQ-151 cream 0.05%;   Drug: ARQ-151 cream 0.15%;   Drug: ARQ-151 cream Vehicle
    Sponsor:   Arcutis Biotherapeutics, Inc.
    Completed
  • Molecular Genetics Studies of Cancer Patients and Their Relatives
    NCT04185935
    Condition:   Malignant Neoplasm
    Interventions:   Other: Biospecimen Collection;   Other: Questionnaire Administration
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting
  • A Study Evaluating the Long-term Safety of VX-445 Combination Therapy
    NCT04043806
    Condition:   Cystic Fibrosis
    Interventions:   Drug: ELX/TEZ/IVA;   Drug: IVA
    Sponsor:   Vertex Pharmaceuticals Incorporated
    Recruiting
  • Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis.
    NCT04036435
    Condition:   Psoriasis
    Intervention:   Drug: BMS-986165
    Sponsor:   Bristol-Myers Squibb
    Recruiting
  • Long-Term PF-06651600 for the Treatment of Alopecia Areata
    NCT04006457
    Condition:   Alopecia Areata
    Intervention:   Drug: PF-06651600
    Sponsor:   Pfizer
    Recruiting
  • Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
    NCT03989206
    Condition:   Moderate-to-Severe Atopic Dermatitis
    Intervention:   Drug: Nemolizumab
    Sponsor:   Galderma R&D
    Not yet recruiting
  • Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis
    NCT03987620
    Condition:   Candida Vulvovaginitis
    Interventions:   Drug: Ibrexafungerp;   Drug: Placebo
    Sponsors:   Scynexis, Inc.;   PPD
    Recruiting
  • Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
    NCT03985943
    Condition:   Moderate-to-Severe Atopic Dermatitis
    Interventions:   Drug: Placebo;   Drug: Nemolizumab
    Sponsor:   Galderma R&D
    Recruiting
  • Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System
    NCT03959423
    Condition:   Type 1 Diabetes Mellitus
    Intervention:   Device: AHCL insulin pump system
    Sponsor:   Medtronic Diabetes
    Recruiting
  • A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)
    NCT03927716
    Condition:   Molluscum Contagiosum
    Interventions:   Drug: SB206 12%;   Drug: Placebo
    Sponsors:   Novan, Inc.;   Synteract, Inc.
    Active, not recruiting
  • Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)
    NCT03893448
    Conditions:   Pneumococcal Infections;   Pneumococcal Vaccines
    Interventions:   Biological: V114;   Biological: Prevnar 13™;   Biological: RotaTeq™;   Biological: Pentacel™;   Biological: RECOMBIVAX HB™;   Biological: VAQTA™;   Biological: M-M-R™;   Biological: VARIVAX™;   Biological: HIBERIX™
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting
  • Study in Subjects With Moderate Atopic Dermatitis
    NCT03859986
    Condition:   Atopic Dermatitis Eczema
    Interventions:   Drug: ALX-101 Gel Vehicle;   Drug: ALX-101 Gel 5%
    Sponsor:   Ralexar Therapeutics, Inc.
    Active, not recruiting
  • A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma
    NCT03847896
    Condition:   Asthma
    Interventions:   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg;   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg;   Combination Product: Budesonide metered-dose inhaler 160 µg;   Combination Product: Albuterol sulfate metered-dose inhaler 180 μg;   Combination Product: Placebo metered-dose inhaler
    Sponsor:   Bond Avillion 2 Development LP
    Recruiting
  • A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma
    NCT03769090
    Condition:   Asthma
    Interventions:   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg;   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg;   Combination Product: Albuterol sulfate metered-dose inhaler 180 μg
    Sponsor:   Bond Avillion 2 Development LP
    Recruiting
  • TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
    NCT03745651
    Condition:   Atopic Dermatitis
    Interventions:   Drug: Ruxolitinib cream;   Drug: Vehicle cream
    Sponsor:   Incyte Corporation
    Active, not recruiting
  • PF-06651600 for the Treatment of Alopecia Areata
    NCT03732807
    Condition:   Alopecia Areata
    Interventions:   Drug: PF-06651600 Induction Dose;   Drug: PF-06651600 Maintenance Dose #1;   Drug: PF-06651600 Maintenance Dose #2;   Drug: PF-06651600 Maintenance Dose #3;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting
  • Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma
    NCT03706079
    Condition:   Asthma
    Interventions:   Biological: Tezepelumab;   Other: Placebo
    Sponsors:   AstraZeneca;   Amgen
    Enrolling by invitation
  • Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
    NCT03633617
    Condition:   Eosinophilic Esophagitis
    Interventions:   Drug: Dupilumab;   Drug: Placebo
    Sponsors:   Regeneron Pharmaceuticals;   Sanofi
    Recruiting
  • A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis
    NCT03607422
    Condition:   Atopic Dermatitis
    Interventions:   Drug: Upadacitinib;   Drug: Placebo for Upadacitinib
    Sponsor:   AbbVie
    Recruiting
  • A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines
    NCT03580369
    Condition:   Chronic Spontaneous Urticaria
    Interventions:   Biological: Ligelizumab;   Biological: Omalizumab;   Other: Placebo
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
    NCT03580356
    Condition:   Chronic Spontaneous Urticaria
    Interventions:   Biological: Ligelizumab;   Biological: Omalizumab;   Other: Placebo
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
    NCT03568318
    Condition:   Atopic Dermatitis
    Interventions:   Drug: Upadacitinib;   Drug: Placebo for Upadacitinib;   Drug: Topical corticosteroids (TCS)
    Sponsor:   AbbVie
    Recruiting
  • An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
    NCT03467958
    Condition:   Crohn Disease
    Intervention:   Drug: Ozanimod
    Sponsor:   Celgene
    Recruiting
  • A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
    NCT03464097
    Condition:   Crohn Disease
    Interventions:   Drug: Ozanimod;   Other: Placebo
    Sponsor:   Celgene
    Recruiting
  • Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment
    NCT03446001
    Condition:   Alzheimer Disease
    Interventions:   Drug: TRx0237 16 mg/day;   Drug: Placebo;   Drug: TRx0237 8 mg/day
    Sponsor:   TauRx Therapeutics Ltd
    Active, not recruiting
  • Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
    NCT03440385
    Condition:   Crohn Disease
    Interventions:   Drug: Ozanimod;   Other: Placebo
    Sponsor:   Celgene
    Recruiting
  • Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma
    NCT03347279
    Condition:   Asthma
    Interventions:   Biological: Experimental: Tezepelumab;   Other: Placebo
    Sponsors:   AstraZeneca;   Amgen
    Active, not recruiting
  • An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1
    NCT03259633
    Condition:   NF type1 With Inoperable Plexiform Neurofibromas
    Intervention:   Drug: Selumetinib
    Sponsor:   AstraZeneca
    Available
  • Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)
    NCT03189875
    Condition:   Systemic Lupus Erythematosus
    Intervention:   Other: Standard of Care
    Sponsor:   AstraZeneca
    Recruiting
  • A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris
    NCT03170388
    Condition:   Acne Vulgaris
    Interventions:   Drug: IDP-126 Gel;   Drug: IDP-126 Component A;   Drug: IDP-126 Component B;   Drug: IDP-126 Component C;   Drug: IDP-126 Vehicle Gel
    Sponsor:   Bausch Health Americas, Inc.
    Completed
  • A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)
    NCT03150719
    Condition:   Cystic Fibrosis
    Interventions:   Drug: Tezacaftor/Ivacaftor;   Drug: Ivacaftor;   Drug: Placebo
    Sponsor:   Vertex Pharmaceuticals Incorporated
    Completed
  • Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo
    NCT03004924
    Condition:   Bacterial Conjunctivitis
    Interventions:   Drug: SHP640;   Drug: PVP-I 0.6%;   Drug: Placebo
    Sponsor:   Shire
    Completed
  • Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome
    NCT02834793
    Condition:   Lennox-Gastaut Syndrome (LGS)
    Interventions:   Drug: Placebo;   Drug: Perampanel
    Sponsor:   Eisai Inc.
    Recruiting
  • Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home
    NCT02748018
    Condition:   Type 1 Diabetes
    Interventions:   Device: 670G Insulin Pump;   Device: Subject's Current Diabetes Therapy
    Sponsor:   Medtronic Diabetes
    Recruiting
  • Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris
    NCT02566369
    Condition:   Acne Vulgaris
    Interventions:   Drug: CD5789 (trifarotene) 50μg/g cream;   Drug: Placebo cream
    Sponsor:   Galderma R&D
    Completed
  • A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis Who Have an F508del-CFTR Mutation
    NCT02565914
    Condition:   Cystic Fibrosis
    Interventions:   Drug: VX-661/ivacaftor;   Drug: ivacaftor
    Sponsor:   Vertex Pharmaceuticals Incorporated
    Enrolling by invitation
  • Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
    NCT02531126
    Condition:   Ulcerative Colitis
    Intervention:   Drug: RPC1063
    Sponsor:   Celgene
    Recruiting
  • Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis
    NCT02435992
    Condition:   Ulcerative Colitis
    Interventions:   Drug: RPC1063;   Drug: Placebo
    Sponsor:   Celgene
    Recruiting
  • Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic Clonic Seizures
    NCT02408549
    Condition:   Epilepsy
    Interventions:   Drug: Lacosamide Tablet;   Drug: Lasosamide Oral Solution
    Sponsor:   UCB BIOSCIENCES, Inc.
    Active, not recruiting
  • A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications
    NCT02408523
    Condition:   Epilepsy
    Interventions:   Drug: Lacosamide Tablet;   Drug: Lasosamide Oral Solution;   Other: Placebo Tablet;   Other: Placebo Oral Solution
    Sponsors:   UCB BIOSCIENCES, Inc.;   Pharmaceutical Research Associates
    Completed
  • Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles
    NCT02269241
    Condition:   Contraception
    Intervention:   Drug: LF111 (drospirenone)
    Sponsors:   Laboratories Leon Farma, S.A.;   Chemo France
    Completed
  • A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters
    NCT02161185
    Condition:   Epilepsy
    Intervention:   Drug: USL261
    Sponsor:   UCB Biopharma S.P.R.L.
    Terminated
  • Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
    NCT02134028
    Condition:   Asthma
    Intervention:   Drug: dupilumab SAR231893 (REGN668)
    Sponsors:   Sanofi;   Regeneron Pharmaceuticals
    Completed
  • Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
    NCT00513695
    Conditions:   Inflammatory Breast Cancer;   Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: sunitinib malate;   Drug: paclitaxel;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: filgrastim;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Other: flow cytometry
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Completed
  • Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
    NCT01767194
    Conditions:   Ganglioneuroblastoma;   Recurrent Neuroblastoma
    Interventions:   Biological: Dinutuximab;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Biological: Sargramostim;   Drug: Temozolomide;   Drug: Temsirolimus
    Sponsors:   National Cancer Institute (NCI);   United Therapeutics
    Completed
  • Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters
    NCT01529034
    Condition:   Epilepsy
    Intervention:   Drug: USL261
    Sponsor:   UCB Biopharma S.P.R.L.
    Terminated
  • Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters
    NCT01390220
    Condition:   Epilepsy
    Interventions:   Drug: USL261;   Drug: Placebo
    Sponsor:   UCB Biopharma S.P.R.L.
    Terminated
  • Web Based Orthopaedic Sports Medicine Registry
    NCT01191151
    Conditions:   Degenerative and Traumatic Pathology of the Knee;   Degenerative and Traumatic Pathology of the Shoulder and Elbow;   Degenerative and Traumatic Pathology of the Foot and Ankle;   Degenerative and Traumatic Pathology of the Hand and Wrist;   Degenerative and Traumatic Pathology of the Hip
    Intervention:  
    Sponsor:   Arthrex, Inc.
    Recruiting
  • Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
    NCT01110733
    Condition:   Peripheral T-cell Lymphoma
    Intervention:  
    Sponsor:   Acrotech Biopharma LLC
    Active, not recruiting
  • Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
    NCT01109004
    Condition:   Multiple Myeloma
    Interventions:   Drug: Lenalidomide;   Drug: lenalidomide, bortezomib and dexamethasone
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
    Completed
  • Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy
    NCT01039376
    Condition:   Leukaemia, Lymphocytic, Chronic
    Interventions:   Biological: Ofatumumab;   Other: Observation
    Sponsor:   Novartis Pharmaceuticals
    Terminated
  • Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma
    NCT00899275
    Condition:   Osteosarcoma
    Intervention:   Other: Cytology Specimen Collection Procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Active, not recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC